The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Blood pressure and the new ACC/AHA hypertension guidelines
Open accessAbstract
The ACC/AHA hypertension guidelines cover virtually all aspects of the diagnosis, evaluation, monitoring, secondary causes as well as drug and non-drug treatment of hypertension. Substantial and appropriate emphasis has been given to the strategies necessary for accurate measurement of blood pressure in any setting where valid blood pressure measurements are desired. Most "errors" made during blood pressure measurement bias readings upwards resulting in over-diagnosis of hypertension and, amongst those already on drug therapy, underestimating the true magnitude of blood pressure lowering resulting in over-treatment. Hypertension is diagnosed when blood pressure is consistently ≥130 and/or ≥80 mm Hg. However, the majority of patients with hypertension between 130-139/80-89 mm Hg (stage 1 hypertension) do not qualify for immediate drug therapy. The guideline breaks new ground with some of its recommendations. Absolute cardiovascular risk is utilized, for the first time, to determine high-risk status when BP 130-139/80-89 mm Hg (Stage 1 hypertension) and high-risk patient characteristics/co-morbidities are absent including age 65 and older, diabetes, chronic kidney disease, known cardiovascular disease; high-risk individuals initiate drug therapy when BP ≥ 130/80 mm Hg. The exception amongst high-risk individuals is for secondary stroke prevention in drug naïve individuals as drug therapy is initiated when blood pressure ≥140/90 mm Hg. Non-high risk individuals will initiate drug therapy when BP is ≥140/90 mm Hg. Irrespective of blood pressure threshold for initiation of drug therapy, the target BP is minimally <130/80 mm Hg in most. However, target BP is <130 systolic amongst those 65 and older as the committee made no recommendation for a DBP target. Treatment should be initiated with two drugs having complementary mechanisms of action when blood pressure is >20/10 mm Hg above goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
Williamson, J. D., Supiano, M. A., Applegate, W. B., Berlowitz, D. R., Campbell, R. C., Chertow, G. M., Fine, L. J., Haley, W. E., Hawfield, A. T., Ix, J. H., et al. (2016) · JAMA · doi:10.1001/jama.2016.7050 · Cited by 1,261
Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232
Revascularization versus Medical Therapy for Renal-Artery Stenosis
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905368 · Cited by 1,193
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Self-citationStenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis
Cooper, C. J., Murphy, T. P., Cutlip, D. E., Jamerson, K., Henrich, W., Reid, D. M., Cohen, D. J., Matsumoto, A. H., Steffes, M., Jaff, M. R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310753 · Cited by 1,021
Bax, L., Woittiez, A.-J. J., Kouwenberg, H. J., Mali, W. P. T. M., Buskens, E., Beek, F. J. A., Braam, B., Huysmans, F. T. M., Schultze Kool, L. J., Rutten, M. J. C. M., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00119 · Cited by 706
Cited by
Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J.-J., Xie, J., Liu, Y.-M., Zhao, Y.-C., Huang, X., Lin, L., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.317134 · Cited by 1,133
“5,6 However, continued use of ACEI/ARB has become controversial in the setting of COVID-19.”
Liu, F., Song, T., Yu, P., Deng, N., Guan, Y., Yang, Y., & Ma, Y. (2023) · Journal of Medical Internet Research · doi:10.2196/43809 · Cited by 72
Siddiqui, K., George, T. P., Joy, S. S., & Alfadda, A. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1079725 · Cited by 59
“Frontiers in Endocrinology 03 Hypertension is diagnosed when blood pressure is consistently ≥130 and/or ≥80mm Hg or be ing managed wi th antihypertensive medications such as angiotensin II receptor antagonist, thiazide diuretic, angiotensin-converting enzyme inhibitor, beta blocker, and calcium channel blockers (15).”
BackgroundAbbas-Hashemi, S. A., Hosseininasab, D., Rastgoo, S., Shiraseb, F., & Asbaghi, O. (2023) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2023.09.923 · Cited by 19
L. P. de Oliveira, V., de Freitas, M. M., P. de Paula, T., Gubert, M. L., Miller, M. E. P., Schuchmann, R. A., Souza, K. L. A., & Viana, L. V. (2024) · Nutrition and Health · doi:10.1177/02601060221124201 · Cited by 8
Metadata
- Authors
- Flack, J. M., & Adekola, B.
- Venue
- Trends in Cardiovascular Medicine
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 30
- Issue
- 3
- Pages
- 160-164
- ISSN
- 1050-1738 (ISSN-L)
- OpenAlex
- W2945447829
- Cited by
- 625
- References
- 24
- FWCI
- 26.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.